Who are Insulin glargine/Lixisenatide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): insulin lispro injection, exenatide injection, Insulin Degludec / Liraglutide Injectable Product, iGlarLixi, insulin glargine/exenatide, Insulin + semaglutide treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/insulin-glargine-lixisenatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Insulin glargine/Lixisenatide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Insulin glargine/Lixisenatide (Insulin glargine/Lixisenatide) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin/GLP-1 receptor agonist combination. Area: Diabetes.

marketed Insulin/GLP-1 receptor agonist combination Insulin receptor; GLP-1 receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Insulin glargine/Lixisenatide (Insulin glargine/Lixisenatide) — Sanofi. This fixed-dose combination provides basal insulin coverage via insulin glargine while lixisenatide, a GLP-1 receptor agonist, enhances glucose-dependent insulin secretion and reduces appetite.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Insulin glargine/Lixisenatide TARGET	Insulin glargine/Lixisenatide	Sanofi	marketed	Insulin/GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
insulin lispro injection, exenatide injection	insulin lispro injection, exenatide injection	The First Affiliated Hospital of Xiamen University	marketed	Insulin analog + GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
Insulin Degludec / Liraglutide Injectable Product	Insulin Degludec / Liraglutide Injectable Product	University of Palermo	marketed	Insulin/GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
iGlarLixi	iGlarLixi	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Insulin/GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
insulin glargine/exenatide	insulin glargine/exenatide	AstraZeneca	phase 3	Insulin/GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
Insulin + semaglutide treatment	Insulin + semaglutide treatment	Centre Hospitalier Universitaire Dijon	phase 3	Insulin + GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin/GLP-1 receptor agonist combination class)

AstraZeneca · 1 drug in this class
Sanofi · 1 drug in this class
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
University of Palermo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin glargine/Lixisenatide — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-lixisenatide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab